Taking this into account, it seems logical that targeting the inflammatory cascade might be more beneficial earlier in the disease course (taking into account the need to avoid immunosuppression in individuals who are at risk for recurrent infection) versus targeting TGF-β that may be more beneficial later in the disease course. This evidence concerns the gene TGFB1 and infection.